Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.
We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.
We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.
Learn more about our Cardio Analysis Services
Experts in cardiac safety
Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.
First patient enrolled in telehealth study, the Pathway Study
25
February 2025
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and the National Amyloidosis Centre and aims...
Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme
17
February 2025
We are committed to embedding Environmental, Social, and Governance (ESG) principles into our clinical research operations to drive responsible and sustainable business growth...
Medicines Marketing UK / EU vs US: Why Your Launch Strategy Needs a Continental Divide - Dr Lisa Campbell, Director of Regulatory Strategy
September 12, 2025
A UK CRO’s perspective on planning clinical trials for global success For pharmaceutical companies preparing for global expansion, launching in both the US and EU / UK markets often seems like the natural next step. Yet success in one region does not guarantee success in the other.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.